Sees Q3 adjusted EBITDA $26M-$30M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYM:
- Symbiotic options imply 14.5% move in share price post-earnings
- Symbotic price target lowered to $29 from $37 at Citi
- Symbotic price target lowered to $18 from $25 at Goldman Sachs
- Symbiotic call volume above normal and directionally bullish
- Symbotic’s Expansion Stagnation and Legal Challenges Signal Potential Stock Decline